Physician profile
Joel J Ackerman
NPI 1457337560
$2,033.03
in general payments reported to CMS, 2019-2025
11 companies · $13.47 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $17.62 · 2021: $294 · 2022: $472 · 2023: $96.45 · 2024: $147 · 2025: $13.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243 · Entertainment: $13.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.46 |
| Entertainment | $13.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $679.64 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $363.27 | 2022-2023 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Johnson & Johnson Vision Care, INC. | $242.14 | 2019-2022 | |
| Alcon Vision LLC | $224.70 | 2019 | |
| Sun Pharmaceutical Industries INC. | $197.05 | 2019-2024 | |
| Shire North American Group INC | $102.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $87.63 | 2019-2021 | |
| Glaukos Corporation | $56.08 | 2022 | |
| Coopervision INC. | $41.72 | 2022 | |
| Nevro Corp. | $24.71 | 2024 | Senza |
| Optos, INC. | $13.47 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.